Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial

Annals of the New York Academy of Sciences

Volumn 949, Issue , 2001, Pages 181-185

  Mosca, Lori ^a,b,c  

^a College of Physicians and Surgeons ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Breast cancer; Clinical trials; Hormone replacement therapy; Menopause; Osteoporosis; Raloxifene; Risk factors; Selective estrogen receptor modulator; Women

Indexed keywords

RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CANCER INVASION; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0035684091     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb04018.x     Document Type: Conference Paper

References (23)

1. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
2. Effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in postmenopausal women: A randomized, controlled trial
3. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
4. The effect of raloxifene on risk of breast cancer in postmenopausal women
5. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium
6. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits
7. Raloxifene and estrogen inhibit neointimal thickening following balloon injury in the carotid artery of male and ovariectomized female rats
8. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HC1)
9. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism
10. Coronary and uterine vascular responses to raloxifene in the sheep
11. A controlled trial of raloxifene (LY139481) HC1: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
12. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
13. The role of hormone replacement therapy in the prevention of postmenopausal heart disease
14. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group
15. Hormone replacement therapy and heart disease prevention: Experimentation trumps observation
16. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) study
17. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
18. Postmenopausal hormone replacement therapy increases risk for thromboembolic disease: The Heart and Estrogen/Progestin Replacement Study
19. Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States: American Heart Association Women's Heart Disease and Stroke Campaign Task Force
20. Design and methods of the Raloxifene Use for the Heart (RUTH) study
21. Design of the Women's Health Initiative clinical trial and observational study
22. Hormone replacement therapy and cardiovascular disease: The case for a randomized controlled trial
23. Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS)